Search

Your search keyword '"Rizzo, J. Douglas"' showing total 277 results
Start Over Author "Rizzo, J. Douglas" Publication Year Range Last 10 years
277 results on '"Rizzo, J. Douglas"'

2. Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry

Author

Schonfeld, Sara J., Valcarcel, Bryan, Meyer, Christa L., Shaw, Bronwen E., Phelan, Rachel, Rizzo, J. Douglas, Brunson, Ann, Cooley, Julianne J. P., Abrahão, Renata, Wun, Ted, Gadalla, Shahinaz M., Engels, Eric, Albert, Paul S., Yusuf, Rafeek, Spellman, Stephen R., Curtis, Rochelle E., Auletta, Jeffery J., Muffly, Lori, Keegan, Theresa H. M., and Morton, Lindsay M.

Published
2024
Full Text
View/download PDF

3. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author

Hong, Sanghee, Brazauskas, Ruta, Hebert, Kyle M, Ganguly, Siddhartha, Abdel‐Azim, Hisham, Diaz, Miguel Angel, Beattie, Sara, Ciurea, Stefan O, Szwajcer, David, Badawy, Sherif M, Gratwohl, Alois A, LeMaistre, Charles, Aljurf, Mahmoud DSM, Olsson, Richard F, Bhatt, Neel S, Farhadfar, Nosha, Yared, Jean A, Yoshimi, Ayami, Seo, Sachiko, Gergis, Usama, Beitinjaneh, Amer M, Sharma, Akshay, Lazarus, Hillard, Law, Jason, Ulrickson, Matthew, Hashem, Hasan, Schoemans, Hélène, Cerny, Jan, Rizzieri, David, Savani, Bipin N, Kamble, Rammurti T, Shaw, Bronwen E, Khera, Nandita, Wood, William A, Hashmi, Shahrukh, Hahn, Theresa, Lee, Stephanie J, Rizzo, J Douglas, Majhail, Navneet S, and Saber, Wael

Subjects
Hematology, Cancer, Clinical Research, Prevention, Transplantation, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Community Health Planning, Female, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Public Health, Risk Factors, Transplantation, Homologous, Treatment Outcome, United States, Young Adult, allogeneic transplant, community health, hematopoietic cell transplantation, survival, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.MethodsThis study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.ResultsThe median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.ConclusionsPatients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.

Published
2021

4. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

Author

Knight, Jennifer M, Costanzo, Erin S, Singh, Suraj, Yin, Ziyan, Szabo, Aniko, Pawar, Deepa S, Hillard, Cecilia J, Rizzo, J Douglas, D'Souza, Anita, Pasquini, Marcelo, Coe, Christopher L, Irwin, Michael R, Raison, Charles L, and Drobyski, William R

Subjects
Clinical Sciences, Public Health and Health Services, Psychology
Abstract

Because medical illness is associated with increased inflammation and an increased risk for treatment-resistant major depressive disorder, anti-cytokine therapy may represent a novel, and especially efficacious, treatment for depression. We hypothesized that blockade of the interleukin (IL)-6 signaling pathway with tocilizumab would decrease depression and related symptomatology in a longitudinal cohort of allogeneic hematopoietic stem cell transplantation (HCT) patients, a medically ill population with a significant inflammation and psychopathology. Patients undergoing allogeneic HCT received either a single dose of tocilizumab one day prior to HCT (n = 25), or HCT alone (n = 62). The primary outcome included depressive symptoms at 28 days post HCT; anxiety, fatigue, sleep, and pain were assessed at pretreatment baseline and days +28, +100, and +180 post HCT as secondary outcomes. Multivariate regression demonstrated that preemptive treatment with tocilizumab was associated with significantly higher depression scores at D28 vs. the comparison group (β = 5.74; 95% CI 0.75, 10.73; P = 0.03). Even after adjustment for baseline depressive symptoms, propensity score, and presence of acute graft-versus-host disease (grades II-IV) and other baseline covariates, the tocilizumab-exposed group continued to have significantly higher depression scores compared to the nonexposed group at D28 (β = 4.73; 95% CI 0.64, 8.81; P = 0.02). Despite evidence that IL-6 antagonism would be beneficial, blockade of the IL-6 receptor with tocilizumab among medically ill patients resulted in significantly more-not less-depressive symptoms.

Published
2021

5. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.

Author

Pulsipher, Michael A, Logan, Brent R, Kiefer, Deidre M, Chitphakdithai, Pintip, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, Susan F, Varni, James W, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Ball, Edward D, Bolwell, Brian J, Bunin, Nancy J, Cheerva, Alexandra, Delgado, David C, Dvorak, Christopher C, Gillio, Alfred P, Hahn, Theresa E, Hale, Gregory A, Haight, Ann E, Hayes-Lattin, Brandon M, Kasow, Kimberly A, Linenberger, Michael, Magalhaes-Silverman, Margarida, Mori, Shahram, Prasad, Vinod K, Quigg, Troy C, Sahdev, Indira, Schriber, Jeffrey R, Shenoy, Shalini, Tse, William T, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Confer, Dennis L, Shaw, Bronwen E, and Switzer, Galen E

Subjects
Humans, Pain, Tissue and Organ Harvesting, Bone Marrow Transplantation, Transplantation, Homologous, Age Factors, Sex Factors, Time Factors, Adolescent, Tissue Donors, Female, Male, BM collection toxicities, Donor safety, PBSC collection toxicities, Stem cell transplantation, Transplantation, Chronic Pain, Neurosciences, Pediatric, Clinical Research, Stem Cell Research, Pain Research, Clinical Trials and Supportive Activities, Prevention, Immunology, Clinical Sciences
Abstract

Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels of pain, symptoms, and long-term recovery are lacking. To address this lack, we prospectively enrolled 294 donors age 20% of females and males age 13 to 17 years do not return to baseline pain levels by 1 year after BM donation. Studies aimed at decreasing symptoms and improving recovery in older children are warranted.

Published
2019

6. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Author

Pulsipher, Michael A, Logan, Brent R, Kiefer, Deidre M, Chitphakdithai, Pintip, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, O’Susan F, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Akard, Luke P, Artz, Andrew S, Ball, Edward D, Bayer, Ruthee-Lu, Bigelow, Carolyn, Bolwell, Brian J, Broun, E Randolph, Delgado, David C, Duckworth, Katharine, Dvorak, Christopher C, Hahn, Theresa E, Haight, Ann E, Hari, Parameswaran N, Hayes-Lattin, Brandon M, Jacobsohn, David A, Jakubowski, Ann A, Kasow, Kimberly A, Lazarus, Hillard M, Liesveld, Jane L, Linenberger, Michael, Litzow, Mark R, Longo, Walter, Magalhaes-Silverman, Margarida, McCarty, John M, McGuirk, Joseph P, Mori, Shahram, Parameswaran, Vinod, Prasad, Vinod K, Rowley, Scott D, Rybka, Witold B, Sahdev, Indira, Schriber, Jeffrey R, Selby, George B, Shaughnessy, Paul J, Shenoy, Shalini, Spitzer, Thomas, Tse, William T, Uberti, Joseph P, Vusirikala, Madhuri, Waller, Edmund K, Weisdorf, Daniel J, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Switzer, Galen E, Confer, Dennis L, and Shaw, Bronwen E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Transplantation, Patient Safety, Regenerative Medicine, Clinical Research, Neurosciences, Stem Cell Research - Nonembryonic - Human, Chronic Pain, Pain Research, Stem Cell Research, Adolescent, Adult, Female, Humans, Living Donors, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation, Peripheral Blood Stem Cells, Prospective Studies, Quality of Life, Unrelated Donors, Young Adult, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Unlike unrelated donor registries, transplant centers lack uniform approaches to related donor assessment and deferral. To test whether related donors are at increased risk for donation-related toxicities, we conducted a prospective observational trial of 11,942 related and unrelated donors aged 18-60 years. Bone marrow (BM) was collected at 37 transplant and 78 National Marrow Donor Program centers, and peripheral blood stem cells (PBSC) were collected at 42 transplant and 87 unrelated donor centers in North America. Possible presence of medical comorbidities was verified prior to donation, and standardized pain and toxicity measures were assessed pre-donation, peri-donation, and one year following. Multivariate analyses showed similar experiences for BM collection in related and unrelated donors; however, related stem cell donors had increased risk of moderate [odds ratios (ORs) 1.42; P

Published
2019

7. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.

Author

Pulsipher, Michael A, Logan, Brent R, Chitphakdithai, Pintip, Kiefer, Deidre M, Riches, Marcie L, Rizzo, J Douglas, Anderlini, Paolo, Leitman, Susan F, Varni, James W, Kobusingye, Hati, Besser, RaeAnne M, Miller, John P, Drexler, Rebecca J, Abdel-Mageed, Aly, Ahmed, Ibrahim A, Akard, Luke P, Artz, Andrew S, Ball, Edward D, Bayer, Ruthee-Lu, Bigelow, Carolyn, Bolwell, Brian J, Broun, E Randolph, Bunin, Nancy J, Delgado, David C, Duckworth, Katharine, Dvorak, Christopher C, Hahn, Theresa E, Haight, Ann E, Hari, Parameswaran N, Hayes-Lattin, Brandon M, Jacobsohn, David A, Jakubowski, Ann A, Kasow, Kimberly A, Lazarus, Hillard M, Liesveld, Jane L, Linenberger, Michael, Litzow, Mark R, Longo, Walter, Magalhaes-Silverman, Margarida, McCarty, John M, McGuirk, Joseph P, Mori, Shahram, Prasad, Vinod K, Rowley, Scott D, Rybka, Witold B, Sahdev, Indira, Schriber, Jeffrey R, Selby, George B, Shaughnessy, Paul J, Shenoy, Shalini, Spitzer, Thomas, Tse, William T, Uberti, Joseph P, Vusirikala, Madhuri, Waller, Edmund K, Weisdorf, Daniel J, Yanik, Gregory A, Navarro, Willis H, Horowitz, Mary M, Switzer, Galen E, Shaw, Bronwen E, and Confer, Dennis L

Subjects
Humans, Peripheral Blood Stem Cell Transplantation, Comorbidity, Adolescent, Adult, Aged, Middle Aged, Blood Donors, Female, Male, Young Adult, Peripheral Blood Stem Cells, BM collection toxicities, Donor safety, PBSC collection toxicities, Stem cell transplantation, Transplantation, Pain Research, Stem Cell Research - Nonembryonic - Human, Clinical Research, Chronic Pain, Stem Cell Research, Aging, Clinical Sciences, Immunology
Abstract

The development of reduced-intensity approaches for allogeneic hematopoietic cell transplantation has resulted in growing numbers of older related donors (RDs) of peripheral blood stem cells (PBSCs). The effects of age on donation efficacy, toxicity, and long-term recovery in RDs are poorly understood. To address this we analyzed hematologic variables, pain, donation-related symptoms, and recovery in 1211 PBSC RDs aged 18 to 79 enrolled in the Related Donor Safety Study. RDs aged > 60 had a lower median CD34+ level before apheresis compared with younger RDs (age > 60, 59 × 106/L; age 41 to 60, 81 × 106/L; age 18 to 40, 121 × 106/L; P < .001). This resulted in older donors undergoing more apheresis procedures (49% versus 30% ≥ 2 collections, P < .001) and higher collection volumes (52% versus 32% > 24 L, P < .001), leading to high percentages of donors aged > 60 with postcollection thrombocytopenia

Published
2019

8. The health risk of social disadvantage is transplantable into a new host.

Author

Turcotte, Lucie M., Tao Wang, Beyer, Kirsten M., Cole, Steven W., Spellman, Stephen R., Allbee-Johnson, Mariam, Williams, Eric, Yuhong Zhou, Verneris, Michael R., Rizzo, J. Douglas, and Knight, Jennifer M.

Subjects
HEMATOPOIETIC stem cell transplantation, SOCIOECONOMIC disparities in health, SOCIAL determinants of health, HEALTH equity, MORTALITY risk factors
Abstract

Low socioeconomic status (SES) is a risk factor for mortality and immune dysfunction across a wide range of diseases, including cancer. However, cancer is distinct in the use of allogeneic hematopoietic cell transplantation (HCT) as a treatment for hematologic malignancies to transfer healthy hematopoietic cells from one person to another. This raises the question of whether social disadvantage of an HCT cell donor, as assessed by low SES, might impact the subsequent health outcomes of the HCT recipient. To evaluate the cellular transplantability of SES-associated health risk, we analyzed the health outcomes of 2,005 HCT recipients who were transplanted for hematologic malignancy at 125 United States transplant centers and tested whether their outcomes differed as a function of their cell donor's SES (controlling for other known HCT-related risk factors). Recipients transplanted with cells from donors in the lowest quartile of SES experienced a 9.7% reduction in overall survival (P = 0.001) and 6.6% increase in treatment-related mortality within 3 y (P = 0.008) compared to those transplanted from donors in the highest SES quartile. These results are consistent with previous research linking socioeconomic disadvantage to altered immune cell function and hematopoiesis, and they reveal an unanticipated persistence of those effects after cells are transferred into a new host environment. These SES-related disparities in health outcomes underscore the need to map the biological mechanisms involved in the social determinants of health and develop interventions to block those effects and enhance the health of both HCT donors and recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018

Author

Valcarcel, Bryan, Schonfeld, Sara J., Meyer, Christa L., Brunson, Ann, Cooley, Julianne J.P., Abrahão, Renata, Wun, Ted, Auletta, Jeffery J., Gadalla, Shahinaz M., Engels, Eric, Albert, Paul S., Spellman, Stephen R., Rizzo, J. Douglas, Shaw, Bronwen E., Muffly, Lori, Keegan, Theresa H.M., and Morton, Lindsay M.

Published
2024
Full Text
View/download PDF

10. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Author

D'Souza, Anita, Fretham, Caitrin, Lee, Stephanie J, Arora, Mukta, Brunner, Janet, Chhabra, Saurabh, Devine, Steven, Eapen, Mary, Hamadani, Mehdi, Hari, Parameswaran, Pasquini, Marcelo C, Perez, Waleska, Phelan, Rachel A, Riches, Marcie L, Rizzo, J Douglas, Saber, Wael, Shaw, Bronwen E, Spellman, Stephen R, Steinert, Patricia, Weisdorf, Daniel J, and Horowitz, Mary M

Published
2020
Full Text
View/download PDF

12. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018

Author

Valcarcel, Bryan, primary, Schonfeld, Sara J., additional, Meyer, Christa L., additional, Brunson, Ann, additional, Cooley, Julianne J.P., additional, Abrahão, Renata, additional, Wun, Ted, additional, Auletta, Jeffery J., additional, Gadalla, Shahinaz M., additional, Engels, Eric, additional, Albert, Paul S., additional, Spellman, Stephen R., additional, Rizzo, J. Douglas, additional, Shaw, Bronwen E., additional, Muffly, Lori, additional, Keegan, Theresa H.M., additional, and Morton, Lindsay M., additional

Published
2023
Full Text
View/download PDF

13. Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research

Author

Auletta, Jeffery J., Kou, Jianqun, Chen, Min, Bolon, Yung-Tsi, Broglie, Larisa, Bupp, Caitrin, Christianson, Debra, Cusatis, Rachel N., Devine, Steven M., Eapen, Mary, Hamadani, Mehdi, Hengen, Mary, Lee, Stephanie J., Moskop, Amy, Page, Kristin M., Pasquini, Marcelo C., Perez, Waleska S., Phelan, Rachel, Riches, Marcie L., Rizzo, J. Douglas, Saber, Wael, Spellman, Stephen R., Stefanski, Heather E., Steinert, Patricia, Tuschl, Eileen, Yusuf, Rafeek, Zhang, Mei-Jie, and Shaw, Bronwen E.

Published
2023
Full Text
View/download PDF

14. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A., Saccardi, Riccardo, Orchard, Kim, Ljungman, Per, Duarte, Rafael F., Labopin, Myriam, McGrath, Eoin, Brook, Nigel, de Elvira, Carmen Ruiz, Gordon, Debra, Poirel, Hélène A., Ayuk, Francis, Beguin, Yves, Bonifazi, Francesca, Gratwohl, Alois, Milpied, Noel, Moore, John, Passweg, Jakob, Rizzo, J. Douglas, Spellman, Stephen R., Sierra, Jorge, Solano, Carlos, Sanchez-Guijo, Fermin, Worel, Nina, Gusi, Andreu, Adams, Gillian, Balan, Theodor, Baldomero, Helen, Macq, Gilles, Marry, Evelyne, Mesnil, Florence, Oldani, Elena, Pearce, Rachel, Perry, Julia, Raus, Nicole, Schanz, Urs, Tran, Steven, Wilcox, Leonie, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Dolstra, Harry, Kuball, Jürgen, Mohty, Mohamad, Lankester, Arjan, Montoto, Sylvia, Nagler, Arnon, Styczynski, Jan, Yakoub-Agha, Ibrahim, de Latour, Regis Peffault, Kroeger, Nicolaus, Brand, Ronald, de Wreede, Liesbeth C., van Zwet, Erik, and Putter, Hein

Published
2020
Full Text
View/download PDF

15. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Author

Radivoyevitch, Tomas, Dean, Robert M., Shaw, Bronwen E., Brazauskas, Ruta, Tecca, Heather R., Molenaar, Remco J., Battiwalla, Minoo, Savani, Bipin N., Flowers, Mary E.D., Cooke, Kenneth R., Hamilton, Betty K., Kalaycio, Matt, Maciejewski, Jaroslaw P., Ahmed, Ibrahim, Akpek, Görgün, Bajel, Ashish, Buchbinder, David, Cahn, Jean-Yves, D’Souza, Anita, Daly, Andrew, DeFilipp, Zachariah, Ganguly, Siddhartha, Hamadani, Mehdi, Hayashi, Robert J., Hematti, Peiman, Inamoto, Yoshihiro, Khera, Nandita, Kindwall-Keller, Tamila, Landau, Heather, Lazarus, Hillard, Majhail, Navneet S., Marks, David I., Olsson, Richard F., Seo, Sachiko, Steinberg, Amir, William, Basem M., Wirk, Baldeep, Yared, Jean A., Aljurf, Mahmoud, Abidi, Muneer H., Allewelt, Heather, Beitinjaneh, Amer, Cook, Rachel, Cornell, Robert F., Fay, Joseph W., Hale, Gregory, Chakrabarty, Jennifer Holter, Jodele, Sonata, Kasow, Kimberly A., Mahindra, Anuj, Malone, Adriana K., Popat, Uday, Rizzo, J. Douglas, Schouten, Harry C., Warwick, Anne B., Wood, William A., Sekeres, Mikkael A., Litzow, Mark R., Gale, Robert P., and Hashmi, Shahrukh K.

Published
2018
Full Text
View/download PDF

17. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors

Author

Hashmi, Shahrukh K., Lee, Stephanie J., Savani, Bipin N., Burns, Linda, Wingard, John R., Perales, Miguel-Angel, Palmer, Jeanne, Chow, Eric, Meyer, Everett, Marks, David, Mohty, Mohamad, Inamoto, Yoshihiro, Rodriguez, Cesar, Nagler, Arnon, Sauter, Craig, Komanduri, Krishna V., Pidala, Joseph, Hamadani, Mehdi, Johnston, Laura, Shah, Nina, Shaughnessy, Paul, Hamilton, Betty K., Majhail, Navneet, Kharfan-Dabaja, Mohamed A., Schriber, Jeff, DeFilipp, Zachariah, Tarlock, Katherine G., Fanning, Suzanne, Curtin, Peter, Rizzo, J. Douglas, and Carpenter, Paul A.

Published
2018
Full Text
View/download PDF

18. Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry

Author

Cusatis, Rachel, Flynn, Kathryn E., Vasu, Sumithira, Pidala, Joseph, Muffly, Lori, Uberti, Joseph, Tamari, Roni, Mattila, Deborah, Mussetter, Alisha, Bruzauskas, Ruta, Chen, Min, Leckrone, Erin, Myers, Judith, Mau, Lih-Wen, Rizzo, J Douglas, Saber, Wael, Horowitz, Mary, Lee, Stephanie J., Burns, Linda J, and Shaw, Bronwen

Published
2022
Full Text
View/download PDF

20. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation

Author

Kanate, Abraham S., Hari, Parameswaran N., Pasquini, Marcelo C., Visotcky, Alexis, Ahn, Kwang W., Boyd, Jennifer, Guru Murthy, Guru Subramanian, Rizzo, J. Douglas, Saber, Wael, Drobyski, William, Michaelis, Laura, Atallah, Ehab, Carlson, Karen S., D'Souza, Anita, Fenske, Timothy S., Cumpston, Aaron, Bunner, Pamela, Craig, Michael, Horowitz, Mary M., and Hamadani, Mehdi

Published
2017
Full Text
View/download PDF

23. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial

Author

Knight, Jennifer M., Syrjala, Karen L., Majhail, Navneet S., Martens, Michael, Le-Rademacher, Jennifer, Logan, Brent R., Lee, Stephanie J., Jacobsen, Paul B., Wood, William A., Jim, Heather S.L., Wingard, John R., Horowitz, Mary M., Abidi, Muneer H., Fei, Mingwei, Rawls, Laura, and Rizzo, J. Douglas

Published
2016
Full Text
View/download PDF

26. Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology

Author

Arber, Daniel A., Borowitz, Michael J., Cessna, Melissa, Etzell, Joan, Foucar, Kathryn, Hasserjian, Robert P., Rizzo, J. Douglas, Theil, Karl, Wang, Sa.A., Smith, Anthony T., Rumble, R. Bryan, Thomas, Nicole E., and Vardiman, James W.

Subjects
Evidence-based medicine -- Usage, Acute leukemia -- Care and treatment -- Diagnosis -- Risk factors, Health, American Society of Hematology, College of American Pathologists
Abstract

* Context.--A complete diagnosis of acute leukemia requires knowledge of clinical information combined with morphologic evaluation, immunophenotyping and karyotype analysis, and often, molecular genetic testing. Although many aspects of the workup for acute leukemia are well accepted, few guidelines have addressed the different aspects of the diagnostic evaluation of samples from patients suspected to have acute leukemia. Objective.--To develop a guideline for treating physicians and pathologists involved in the diagnostic and prognostic evaluation of new acute leukemia samples, including acute lymphoblastic leukemia, acute myeloid leukemia, and acute leukemias of ambiguous lineage. Design.--The College of American Pathologists and the American Society of Hematology convened a panel of experts in hematology and hematopathology to develop recommendations. A systematic evidence review was conducted to address 6 key questions. Recommendations were derived from strength of evidence, feedback received during the public comment period, and expert panel consensus. Results.--Twenty-seven guideline statements were established, which ranged from recommendations on what clinical and laboratory information should be available as part of the diagnostic and prognostic evaluation of acute leukemia samples to what types of testing should be performed routinely, with recommendations on where such testing should be performed and how the results should be reported. Conclusions.--The guideline provides a framework for the multiple steps, including laboratory testing, in the evaluation of acute leukemia samples. Some aspects of the guideline, especially molecular genetic testing in acute leukemia, are rapidly changing with new supportive literature, which will require on-going updates for the guideline to remain relevant. (Arch Pathol Lab Med. 2017;141:1342-1393; doi: 10.5858/arpa.2016-0504-CP), The laboratory evaluation of patients suspected of having acute leukemia (AL) is complex and has evolved significantly with the incorporation of advanced laboratory techniques. The first broadly accepted classification in [...]

Published
2017
Full Text
View/download PDF

27. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Saccardi, Riccardo, primary, Putter, Hein, additional, Eikema, Dirk-Jan, additional, Busto, María Paula, additional, McGrath, Eoin, additional, Middelkoop, Bas, additional, Adams, Gillian, additional, Atlija, Marina, additional, Ayuk, Francis Ayuketang, additional, Baldomero, Helen, additional, Beguin, Yves, additional, de la Cámara, Rafael, additional, Cedillo, Ángel, additional, Balari, Anna María Sureda, additional, Chabannon, Christian, additional, Corbacioglu, Selim, additional, Dolstra, Harry, additional, Duarte, Rafael F., additional, Dulery, Rémy, additional, Greco, Raffaella, additional, Gusi, Andreu, additional, Hamad, Nada, additional, Kenyon, Michelle, additional, Kröger, Nicolaus, additional, Labopin, Myriam, additional, Lee, Julia, additional, Ljungman, Per, additional, Manson, Lynn, additional, Mensil, Florence, additional, Milpied, Noel, additional, Mohty, Mohamad, additional, Oldani, Elena, additional, Orchard, Kim, additional, Passweg, Jakob, additional, Pearce, Rachel, additional, de Latour, Régis Peffault, additional, Poirel, Hélène A., additional, Rintala, Tuula, additional, Rizzo, J. Douglas, additional, Ruggeri, Annalisa, additional, Sanchez-Martinez, Carla, additional, Sanchez-Guijo, Fermin, additional, Sánchez-Ortega, Isabel, additional, Trnková, Marie, additional, Ferreiras, David Valcárcel, additional, Wilcox, Leonie, additional, de Wreede, Liesbeth C., additional, and Snowden, John A., additional

Published
2023
Full Text
View/download PDF

28. Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Author

Sharma, Akshay, primary, Logan, Brent, additional, Estrada-Merly, Noel, additional, Lehmann, Leslie E., additional, Rangarajan, Hemalatha G., additional, Preussler, Jaime M., additional, Troy, Jesse D, additional, Akard, Luke P, additional, Bhatt, Neel S., additional, Truong, Tony H, additional, Wood, William, additional, Rizzo, J. Douglas, additional, and Saber, Wael, additional

Published
2023
Full Text
View/download PDF

29. Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report from the BMT CTN Patient and Caregiver Advocacy Task Force

Author

Vasu, Sumithira, primary, Holtan, Shernan Grace, additional, Shimamura, Akiko, additional, Burnworth, Todd, additional, Whisenton, Shauna, additional, Adams, Sanderson, additional, Nuechterlein, Brandon, additional, Mortier, Nicole, additional, Foster, Jackie, additional, DiFronzo, Nancy, additional, Horowitz, Mary M., additional, Rizzo, J. Douglas, additional, and Foley, Amy, additional

Published
2023
Full Text
View/download PDF

30. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A., Saccardi, Riccardo, Orchard, Kim, Ljungman, Per, Duarte, Rafael F., Labopin, Myriam, McGrath, Eoin, Brook, Nigel, de Elvira, Carmen Ruiz, Gordon, Debra, Poirel, Hélène A., Ayuk, Francis, Beguin, Yves, Bonifazi, Francesca, Gratwohl, Alois, Milpied, Noel, Moore, John, Passweg, Jakob, Rizzo, J. Douglas, Spellman, Stephen R., Sierra, Jorge, Solano, Carlos, Sanchez-Guijo, Fermin, Worel, Nina, Gusi, Andreu, Adams, Gillian, Balan, Theodor, Baldomero, Helen, Macq, Gilles, Marry, Evelyne, Mesnil, Florence, Oldani, Elena, Pearce, Rachel, Perry, Julia, Raus, Nicole, Schanz, Urs, Tran, Steven, Wilcox, Leonie, Basak, Grzegorz W., Chabannon, Christian, Corbacioglu, Selim, Dolstra, Harry, Kuball, Jürgen, Mohty, Mohamad, Lankester, Arjan, Montoto, Sylvia, Nagler, Arnon, Styczynski, Jan, Yakoub-Agha, Ibrahim, de Latour, Regis Peffault, Kroeger, Nicolaus, Brand, Ronald, de Wreede, Liesbeth C., van Zwet, Erik, and Putter, Hein

Published
2020
Full Text
View/download PDF

34. Effect of Cord Blood Processing on Transplantation Outcomes after Single Myeloablative Umbilical Cord Blood Transplantation

Author

Ballen, Karen K., Logan, Brent R., Laughlin, Mary J., He, Wensheng, Ambruso, Daniel R., Armitage, Susan E., Beddard, Rachel L., Bhatla, Deepika, Hwang, William Y.K., Kiss, Joseph E., Koegler, Gesine, Kurtzberg, Joanne, Nagler, Arnon, Oh, David, Petz, Lawrence D., Price, Thomas H., Quinones, Ralph R., Ratanatharathorn, Voravit, Rizzo, J. Douglas, Sazama, Kathleen, Scaradavou, Andromachi, Schuster, Michael W., Sender, Leonard S., Shpall, Elizabeth J., Spellman, Stephen R., Sutton, Millicent, Weitekamp, Lee Ann, Wingard, John R., and Eapen, Mary

Published
2015
Full Text
View/download PDF

35. Corrigendum to ‘Current Use and Trends in Hematopoietic Cell Transplantation in the United States’ [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]

Author

D'Souza, Anita, primary, Fretham, Caitrin, additional, Lee, Stephanie J., additional, Arora, Mukta, additional, Brunner, Janet, additional, Chhabra, Saurabh, additional, Devine, Steven, additional, Eapen, Mary, additional, Hamadani, Mehdi, additional, Hari, Parameswaran, additional, Pasquini, Marcelo C., additional, Perez, Waleska, additional, Phelan, Rachel A., additional, Riches, Marcie L., additional, Rizzo, J. Douglas, additional, Saber, Wael, additional, Shaw, Bronwen E., additional, Spellman, Stephen R., additional, Steinert, Patricia, additional, Weisdorf, Daniel J., additional, and Horowitz, Mary M., additional

Published
2022
Full Text
View/download PDF

36. Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]

Author

Chhabra, Saurabh, primary, Visotcky, Alexis, additional, Pasquini, Marcelo C., additional, Zhu, Fenlu, additional, Tang, Xiaoying, additional, Zhang, Mei-Jie, additional, Thompson, Robert, additional, Abedin, Sameem, additional, D'Souza, Anita, additional, Dhakal, Binod, additional, Drobyski, William R., additional, Fenske, Timothy S., additional, Jerkins, James H., additional, Rizzo, J. Douglas, additional, Runaas, Lyndsey, additional, Saber, Wael, additional, Shah, Nirav N., additional, Shaw, Bronwen E., additional, Horowitz, Mary M., additional, Hari, Parameswaran N., additional, and Hamadani, Mehdi, additional

Published
2022
Full Text
View/download PDF

42. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation

Author

Knight, Jennifer M., Kerswill, Stephanie A., Hari, Parameswaran, Cole, Steve W., Logan, Brent R., D’Souza, Anita, Shah, Nirav N., Horowitz, Mary M., Stolley, Melinda R., Sloan, Erica K., Giles, Karen E., Costanzo, Erin S., Hamadani, Mehdi, Chhabra, Saurabh, Dhakal, Binod, and Rizzo, J. Douglas

Published
2018
Full Text
View/download PDF

45. COVID-19 and Hematopoietic Cell Transplant Center-specific survival analysis: Can we adjust for the impact of the pandemic? Recommendations of the COVID-19 Taskforce of the 2020 CIBMTR Center Outcomes Forum

Author

Wingard, John R., Ahn, Kwang Woo, Dandoy, Christopher, Perales, Miguel-Angel, Wood, William A., Logan, Brent, Riches, Marcie, and Rizzo, J. Douglas

Subjects
Bone Marrow, SARS-CoV-2, Hematopoietic Stem Cell Transplantation, COVID-19, Humans, Pandemics, Article
Abstract

COVID-19 has significantly impacted the practice of hematopoietic cell transplantation (HCT) and likely affected outcomes of HCT recipients. Early reports document substantially higher case fatality rates for HCT recipients than faced by the general population. The threat to individual patients is real, but at present, we do not have a clear picture of how much of this threat is present within the first year after HCT, as the majority of cases in early reports occurred after the first year. Still unknown is how infection rates and outcomes vary with time after HCT. This is important because center-specific survival estimates for reporting purposes focus on 1-year post-HCT mortality. Transplant centers have dramatically changed practices due to the pandemic. For many centers, quality assurance processes and procedures were disrupted, and these changes likely affected team performance. Centers have been affected unevenly by the pandemic, by time, location, and COVID-19 burden. Assessment of center-specific survival depends on the ability to adjust for risk factors such as COVID-19 that are outside center control using consistent methods so that team performance based on controllable risk factors can be ascertained. The Center of International Blood and Marrow Transplantation Research (CIBMTR) convened a working group for the 2020 Center Outcomes Forum (COF) to assess the impact of COVID-19 on both patient-specific risks and center-specific performance. This committee reviewed the factors at play and developed recommendations for a process to determine if adjustments in the methodology to assess center-specific performance are needed.

Published
2021

49. Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Author

Snowden, John A, Saccardi, Riccardo, Orchard, Kim, Ljungman, Per, Duarte, Rafael F, Labopin, Myriam, McGrath, Eoin, Brook, Nigel, de Elvira, Carmen Ruiz, Gordon, Debra, Poirel, Hélène A, Ayuk, Francis, Beguin, Yves, Bonifazi, Francesca, Gratwohl, Alois, Milpied, Noel, Moore, John, Passweg, Jakob, Rizzo, J Douglas, Spellman, Stephen R, Sierra, Jorge, Solano, Carlos, Sanchez-Guijo, Fermin, Worel, Nina, Gusi, Andreu, Adams, Gillian, Balan, Theodor, Baldomero, Helen, Macq, Gilles, Marry, Evelyne, et al, University of Zurich, and Snowden, John A

Subjects
2747 Transplantation, 10032 Clinic for Oncology and Hematology, 2720 Hematology, 610 Medicine & health
Published
2020

50. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States

Author

Hong, Sanghee, primary, Brazauskas, Ruta, additional, Hebert, Kyle M., additional, Ganguly, Siddhartha, additional, Abdel‐Azim, Hisham, additional, Diaz, Miguel Angel, additional, Beattie, Sara, additional, Ciurea, Stefan O., additional, Szwajcer, David, additional, Badawy, Sherif M., additional, Gratwohl, Alois A., additional, LeMaistre, Charles, additional, Aljurf, Mahmoud D. S. M., additional, Olsson, Richard F., additional, Bhatt, Neel S., additional, Farhadfar, Nosha, additional, Yared, Jean A., additional, Yoshimi, Ayami, additional, Seo, Sachiko, additional, Gergis, Usama, additional, Beitinjaneh, Amer M., additional, Sharma, Akshay, additional, Lazarus, Hillard, additional, Law, Jason, additional, Ulrickson, Matthew, additional, Hashem, Hasan, additional, Schoemans, Hélène, additional, Cerny, Jan, additional, Rizzieri, David, additional, Savani, Bipin N., additional, Kamble, Rammurti T., additional, Shaw, Bronwen E., additional, Khera, Nandita, additional, Wood, William A., additional, Hashmi, Shahrukh, additional, Hahn, Theresa, additional, Lee, Stephanie J., additional, Rizzo, J. Douglas, additional, Majhail, Navneet S., additional, and Saber, Wael, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results